Skip to main content
Infant Bacterial Therapeutics logo

Infant Bacterial Therapeutics — Investor Relations & Filings

Ticker · IBT ISIN · SE0008015259 LEI · 2138008KVBXCRJGP6Z26 ST Manufacturing
Open in API
Filings indexed 212 across all filing types
Latest filing 2019-08-22 Major Shareholding Noti…
Country SE Sweden
Listing ST IBT

About Infant Bacterial Therapeutics

https://ibtherapeutics.com/

Infant Bacterial Therapeutics (IBT) is a pharmaceutical company that develops drugs influencing the human infant microbiome to prevent or treat rare diseases. The company's primary focus is on premature infants, addressing urgent medical needs such as necrotizing enterocolitis (NEC), a potentially lethal inflammatory bowel disorder. Its lead drug candidate, IBP-9414, is a New Biological Entity (NBE) currently in a Phase 3 clinical study. IBT also aims to develop treatments for diseases caused by antibiotic-resistant bacteria. The company is developing its medicines for approval by regulatory agencies, including the FDA and EMA.

Recent filings

Filing Released Lang Actions
Major Shareholding Notification 2019
Major Shareholding Notification Classification · 99% confidence The document details a change in shareholding for 'Swedbank Robur Fonder AB' in 'Infant Bacterial Therapeutics AB'. It explicitly states the 'Reason for major shareholding notification Buy' and shows the 'Before the transaction' and 'After the transaction' share quantities and resulting voting rights percentages (crossing the 5% limit). This structure is characteristic of a notification regarding a change in significant ownership thresholds. This aligns directly with the definition for Major Shareholding Notification (MRQ). The document is short and contains specific transactional data, not a general announcement of a report.
2019-08-22 English
Interim / Quarterly Report 2018
Interim / Quarterly Report Classification · 95% confidence The document is titled 'Year-end report January 1-December 31, 2018' and provides comprehensive financial statements, including net sales, operating loss, earnings per share, cash flow, and balance sheet data for the full year and the fourth quarter. It includes detailed management commentary, notes on financial risks, and significant events. As it covers a period shorter than a full fiscal year (in the context of a year-end report which is distinct from a full 10-K/Annual Report) and contains substantive financial data, it is classified as an Interim/Quarterly Report. FY 2018
2019-08-02 English
Infant Bacterial Therapeutics har rekryterat den första patienten i den pivotala kliniska Fas III-studie
Regulatory Filings Classification · 95% confidence The document is a press release dated July 4, 2019, announcing a significant operational milestone: the recruitment of the first patient in a pivotal Phase III clinical study (The Connection Study) for their drug candidate IBP-9414. It details the study parameters, regulatory approvals (FDA, EMA), and includes quotes from the CEO. The final section explicitly states that the information is being made public according to EU Market Abuse Regulation and Nasdaq rules, indicating it is a formal regulatory disclosure. This content is not a full Annual Report (10-K), an Earnings Release (ER), a Call Transcript (CT), or a detailed Investor Presentation (IP). It is a specific announcement regarding clinical trial progress and regulatory compliance. Since it is a formal announcement of a material event required for public disclosure, and it doesn't fit the specific categories like Director's Dealing (DIRS), Dividend Notice (DIV), or Capital Change (CAP), it falls best under the general regulatory disclosure category, 'Regulatory Filings' (RNS), as it is a mandatory public disclosure of a material event. However, given the specific nature of the announcement (clinical trial progress), if a more specific category existed for clinical trial updates, that would be preferred. Since it is a general press release announcing a material event under market abuse rules, RNS is the most appropriate fallback among the provided options, although it is very close to an 'ER' in structure (a brief announcement of key operational news). Given the focus on clinical trial progress and not financial results, RNS is chosen over ER.
2019-07-04 Swedish
Infant Bacterial Therapeutics has recruited the first patient in the pivotal Phase III clinical study
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "Press Release" dated July 4, 2019, announcing a significant operational milestone: recruiting the first patient in a pivotal Phase III clinical study (The Connection Study) for their drug candidate IBP-9414. It details the study parameters, regulatory approvals (FDA, EMA), and includes quotes from the CEO. The final section states that this information is "obliged to make public pursuant to the EU Market Abuse Regulation and which is to be made public according to the Nasdaq regulations for companies listed on Nasdaq Stockholm." This structure—a time-sensitive announcement of a material event released via press release to satisfy regulatory disclosure requirements—fits best under the general category for miscellaneous regulatory announcements, which is Regulatory Filings (RNS), as it is not a specific financial report (10-K, IR, ER) or a specific corporate action like a dividend or management change. It is a general operational update disclosed publicly.
2019-07-04 English
FDA och Infant Bacterial Therapeutics överens rörande Fas III studiens utformning
Regulatory Filings Classification · 95% confidence The document is explicitly labeled as a "Press Release" dated May 19, 2019. It discusses an agreement with the FDA regarding the design of a Phase III study for a drug candidate (IBP-9414). This content relates to clinical development plans, regulatory interactions (FDA, EMA), and future trial initiation. This type of announcement, which is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), falls best under general regulatory announcements or updates that impact the company's operations and pipeline. Since it is a specific announcement about regulatory/clinical progress rather than a general corporate event (like a board change or dividend), and it doesn't fit the specific definitions for LTR (Legal Proceedings), CAP (Financing), or DIV, the most appropriate general category for significant, non-financial regulatory updates that are disseminated via press release is Regulatory Filings (RNS). The document length is short (3794 chars) and it is a direct announcement, not a report itself.
2019-05-19 English
FDA and Infant Bacterial Therapeutics agree on the design of Phase III study
Legal Proceedings Report Classification · 99% confidence The document is explicitly labeled as a "Press Release" dated May 19, 2019. It discusses an agreement with the FDA regarding the design of a Phase III study for a drug candidate (IBP-9414). This content relates to clinical development plans, regulatory interactions (FDA, EMA), and future trial initiation. This type of announcement, which is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), falls best under general regulatory announcements or updates that impact the company's operations and pipeline. Since it is a specific announcement about regulatory/clinical progress rather than a general corporate event (like a board change or dividend), and it doesn't fit the specific definitions for LTR (Legal Proceedings), CAP (Financing), or DIV, the most appropriate general category for significant, non-financial regulatory updates that are disseminated via press release is Regulatory Filings (RNS). The document length is short (3794 chars) and it is a direct announcement, not a report itself.
2019-05-19 English

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.